ATNM:NYE-Actinium Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 7.75

Change

0.00 (0.00)%

Market Cap

USD 0.11B

Volume

0.52M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York. Address: 275 Madison Avenue, New York, NY, United States, 10016

Company Website : http://www.actiniumpharma.com

Address : 275 Madison Avenue, New York, NY, United States, 10016

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.07

52 Week High : 19.47

Short Ratio : 1.51

52 Week Low : 4.71

Shorted Shares : 701,517

200 Day Moving Average : 9.71

Shorted Shares Previous Month : 1,018,770

50 Day Moving Average : 8.58

Shares Held By Insiders : 15.46%

Short Percentage : 5.00%

Shares Held by Institutions : 22.05%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

 USD163.53B 28.27 2.82
ADPT Adaptive Biotechnologies Corpo..

N/A

 USD5.88B 43.96 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

 USD5.20B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

 USD2.37B N/A N/A
MYOV Myovant Sciences Ltd

N/A

 USD1.99B N/A N/A
ADCT ADC Therapeutics SA

N/A

 USD1.75B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

 USD1.52B 300.20 N/A
CVM CEL-SCI Corporation

N/A

 USD0.79B N/A N/A
RFL Rafael Holdings, Inc

N/A

 USD0.51B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

 USD4.81M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.64% 29% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.64% 29% F 31% F
Trailing 12 Months  
Capital Gain -12.13% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.13% 20% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.84% 48% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.84% 48% F 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 31.94% 64% D 19% F
Risk Adjusted Return 58.97% 72% C- 70% C-
Market Capitalization 0.11B 39% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.41 92% A- 41% F
Price / Cash Flow Ratio -4.91 29% F 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -73.83% 52% F 6% F
Return on Invested Capital -292.59% 19% F 0% N/A
Return on Assets -38.51% 37% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.51 50% F 57% F
Short Percent 5.17% 44% F 45% F
Beta 1.07 68% D+ 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.